Ask about this productRelated genes to: SULT1E1 Blocking Peptide
- Gene:
- SULT1E1 NIH gene
- Name:
- sulfotransferase family 1E member 1
- Previous symbol:
- STE
- Synonyms:
- EST
- Chromosome:
- 4q13.3
- Locus Type:
- gene with protein product
- Date approved:
- 1994-05-18
- Date modifiied:
- 2016-10-05
Related products to: SULT1E1 Blocking Peptide
Related articles to: SULT1E1 Blocking Peptide
- : Meningiomas, the most common primary intracranial tumors, are predominantly benign, but high-grade variants show marked aggressiveness, histo-molecular heterogeneity, and treatment resistance. Although the 2021 WHO CNS classification integrates molecular and histopathologic criteria, substantial inter- and intratumoral variability still limits prognostic accuracy and treatment effectiveness. The goal was to provide insight regarding the histo-molecular intratumoral heterogeneity (ITH) of meningioma and examine its clinical implications. : A narrative review was performed in accordance with PRISMA guidelines. PubMed and Google Scholar were screened for studies on "meningioma" and "intratumoral heterogeneity" published up to 28 July 2025. Eligible studies included original human research reporting histological or molecular heterogeneity with clinical relevance. : Eighteen studies comprising 2952 meningioma patients (mean age 59.4 ± 14.8 years, range 16-85) were included. Integrated cytogenetic, molecular, and spatial analyses, including FISH, karyotyping, scRNA-seq, CNV profiling, and spatial transcriptomics, revealed multilayered histo-molecular heterogeneity. Histologically, regional variations in morphology and proliferative index increased with tumor grade. Genomic diversity, marked by recurrent losses of 1p, 14q, and 22q and transcriptionally distinct subclones, defined a complex tumor architecture. Spatial and temporal analyses demonstrated subclonal expansion, stepwise clonal evolution, and therapy resistance, particularly in recurrent tumors. Functionally, SULT1E1 subclones and COL6A3-mediated macrophage-tumor interactions emerged as potential key drivers of malignancy, recurrence, and radioresistance. : Histo-molecular diversity underlies meningioma progression, recurrence, and therapeutic resistance. Standardization of ITH assessment, integration of AI-based spatial analytics, and the development of subclone-specific therapies are essential next steps toward advancing precision neuro-oncology. - Source: PubMed
Publication date: 2026/04/10
Bankole Nourou Dine AdeniranLe Van TuanKerherve LucMorlaix EdouardBellus Jean-FrançoisBelhajali KerimaLopez JulianDe Buck PierreHouidi Alia SaydaFarah WalidLleu MaximeBaland OlivierCao CathyEl Cadhi AhmedBeaurain JacquesPicart ThiebaudBerhouma Moncef - This study investigated whether these contrasting environments are associated with the development of coherent, organism-wide phenotypic-physiological syndromes reflecting a fundamental life-history trade-off. A controlled 60-day trial was conducted comparing crayfish from a high-input pond system (fed to satiation) and a low-input rice paddy system (primarily natural diet). Pond crayfish were fed a commercial formulated feed twice daily to satiation (approximately 3% of biomass per day). Rice paddy crayfish primarily consumed natural food webs and received a once-daily supplement of 30% of the pond feed amount (approximately 0.9% of biomass per day). Results revealed two distinct syndromes. Pond-cultured crayfish exhibited a growth-oriented syndrome: they were 33% heavier with a compact, volumetrically enhanced body shape, coupled with elevated lipid-anabolic enzyme activities (lipase and ACC), higher hemolymph protein and cholesterol concentrations, but also significantly increased levels of a stress-related endocrine factor (cortisol-like immunoreactivity) and oxidative damage (MDA). Conversely, rice paddy-cultured crayfish displayed a stress-resistance-oriented syndrome: a streamlined, deeper-abdomen morphology, fortified antioxidant (SOD, CAT, and GST) and immune (lysozyme and phenoloxidase) capacities, enhanced carbohydrate digestion (amylase), and lower systemic stress. Transcriptomic analysis showed that the hepatopancreas of paddy-cultured crayfish was enriched in pathways related to lipid metabolism, detoxification, and endocrine regulation, notably with upregulation of the gene. Our findings demonstrate that the distinct environmental and nutritional conditions of each aquaculture system are linked to specific multi-level adaptation syndromes, presenting a clear trade-off between rapid biomass production and systemic stress resistance (within the 60-day trial period), providing a mechanistic basis for optimizing sustainable practices: integrated systems enhance stock robustness, while intensive systems require strategies to mitigate physiological load. - Source: PubMed
Publication date: 2026/04/16
Gao GaoGan LingyuWei JingnanLuo HongWang HuiyingChen JialongSu XiaoyiLi ZhangxiuBi BaoliangJia Dan - : Tamoxifen is widely used in the treatment of hormone receptor-positive breast cancer and has been shown to successfully reduce recurrence and mortality rates. Nonetheless, variability in patient response to tamoxifen treatment is observed with up to 40% of patients experiencing recurrence. Genetic polymorphisms in pharmacogenes encoding enzymes involved in tamoxifen metabolism have been linked to some of this observed interindividual variability. The pharmacogenetics of tamoxifen in populations of African descent remain understudied, creating difficulties in pinpointing the primary factors behind the observed variable response. To address this gap, this study aimed to investigate the role of genetic variation in tamoxifen treatment outcomes in a South African cohort. : Participants included 166 Mixed and African Ancestry breast cancer patients who had received tamoxifen treatment. Genetic characterization was performed for 53 single nucleotide polymorphisms (SNPs) and two copy number variations across eight drug-metabolizing enzymes, including cytochrome P450s (, , , ), UDP-glucuronosyltransferases (), and sulfotransferases (, , ). The association between genotypes and disease-free survival (DFS) was evaluated using Cox proportional hazards regression models. : The or * genotype showed a nominal association with improved DFS ( = 0.049), with a similar trend observed for rs11888492. In contrast, rs3775779 heterozygosity showed a nominal association with reduced DFS ( = 0.044). SNPs (rs4149393, rs4149394, rs1042157) demonstrated trends toward reduced DFS. : These exploratory findings highlight the need for more inclusive pharmacogenomic research and point to potential biomarkers for optimizing tamoxifen therapy in African populations. - Source: PubMed
Publication date: 2026/03/31
Kruger BiancaChimusa Emile RAbera Aron BSingh JesmikaShamley DelvaDandara Collet - Cholestatic liver diseases, such as primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and biliary atresia (BA), are characterized by bile accumulation and frequently progress to liver fibrosis, cirrhosis, and organ failure. - Source: PubMed
Publication date: 2026/04/09
Pan DiZheng TianChen CanpingQiu JieDeng ZhijuanJiang ZhaohuiChen YanXiao ChaodaXu YiniFu LingyunLinghu KegangChen JiyuFan FangfangZhang QingxiuTao LingHu XiaoxiaZhao LiShen Xiangchun - : Tamoxifen remains the cornerstone of endocrine therapy for hormone receptor-positive breast cancer across Africa. Understanding the factors that influence tamoxifen tolerability is critical, as treatment-related side effects can reduce adherence and compromise therapeutic outcomes. Yet, the contribution of pharmacogenetic variation to tamoxifen-related toxicity remains poorly characterized in African populations. This study, therefore, investigated whether genetic variation in key pharmacogenes influences the risk of treatment-related side effects in a South African breast cancer cohort. : A total of 166 women of Mixed and African Ancestry treated with 20 mg/day tamoxifen at Groote Schuur Hospital, South Africa, were included in the study. Genetic variation across 28 variants in nine pharmacogenes, including , , , , , and , was assessed using various genotyping methods. Associations between genetic and non-genetic factors and tamoxifen side effects were evaluated with logistic regression. : Over 70% of participants reported at least one treatment-related side effect. Overall side-effect burden was associated with copy number variation ( = 0.030) and rs3736599 ( = 0.042). Musculoskeletal complaints were the most common (40%) and were associated with rs7439366 ( = 0.040) and rs2242480 ( = 0.051). Gynecological symptoms affected more than 20% of participants and were linked to ( = 0.050), rs3736599 ( = 0.016), and rs4148269 ( = 0.039). Hot flashes were frequent, affecting 33% of patients, but showed no clear pharmacogenetic associations. : This study demonstrates that pharmacogenetic variation is associated with interindividual differences in treatment-related side effects, underscoring the need to expand research in African populations to better inform precision endocrine therapy. - Source: PubMed
Publication date: 2026/02/24
Kruger BiancaChimusa EmileAbera AronSingh JesmikaShamley DelvaDandara Collet